Mar 2026 $2 M Private placement after listing Under $2 million 1
Kala Pharmaceuticals, Inc.: Private sale, Mar 2026 × Investors in this round 1 investor had bought by the notice of Mar 17, 2026: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken $1,753,500
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Avi Minkowitz · Executive Officer, Director Brendan Purdy · Director Chaim Berger · Director Hillel Posen · Director Yonatan Colman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The total offering amount is based off the closing price of KALA BIO, Inc.'s common stock on March 3, 2026 ($0.3507) for 5 million shares of common stock being issued.”Signed by Avi Minkowitz, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 17, 2026. Read the notice at the SEC .
equity SEC Jan 2026 $2 M Private placement after listing $2 to $10 million 20
Kala Pharmaceuticals, Inc.: Private sale, Jan 2026 × Investors in this round 20 investors had bought by the notice of Feb 13, 2026: 20 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $4 M offered; $2 M still to sell
Smallest investment taken $44,905
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $38,988
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Avi Minkowitz · Executive Officer, Director · Chief Executive Officer, Chief Financial Officer and Director Brendan Purdy · Director · Director Chaim Berger · Director · Director David Lazar · Director · Director Hillel Posen · Director · Director Yonatan Colman · Director · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round FM Global Markets Inc. (CRD 000174843) · Toronto, Canada (Federal Level) Sold in CO, DE, FL, NY, WY, and outside the US Remarks in the notice On the amounts: “The issuer issued 1,125,300 shares of Series AAA Preferred Stock at $2.00 per share for aggregate proceeds of $2,250,600 in a private placement pursuant to Rule 506(b) of Reg. D and 974,700 shares pursuant to Rule 903 of Reg. S.”Signed by Avi Minkowitz, CEO, CFO and Director. Source: SEC Form D, newest notice filed Feb 13, 2026. Read the notice at the SEC .
equity SEC Dec 2024 $11 M Private placement after listing $10 to $50 million 6
Kala Pharmaceuticals, Inc.: Private sale, Dec 2024 × Investors in this round 6 investors had bought by the notice of Dec 31, 2024: 6 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $11 M of $11 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Darius Kharabi · Executive Officer Kim Brazzell · Executive Officer Mark Iwicki · Executive Officer, Director Mary Reumuth · Executive Officer Todd Bazemore · Executive Officer Andrew I. Koven · Director C. Daniel Myers · Director Gregory D. Perry · Director Howard B. Rosen · Director Marjan D. Farid · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Mary Reumuth, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 31, 2024. Read the notice at the SEC .
equity SEC Jun 2024 $13 M Private placement after listing $10 to $50 million 5
Kala Pharmaceuticals, Inc.: Private sale, Jun 2024 × Investors in this round 5 investors had bought by the notice of Jun 28, 2024: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $13 M of $13 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Darius Kharabi · Executive Officer Kim Brazzell · Executive Officer Mark Iwicki · Executive Officer, Director Mary Reumuth · Executive Officer Todd Bazemore · Executive Officer Andrew I. Koven · Director C. Daniel Myers · Director Gregory D. Perry · Director Howard B. Rosen · Director Marjan D. Farid · Director Mark S. Blumenkranz · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Mary Reumuth, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 28, 2024. Read the notice at the SEC .
equity SEC Nov 2021 $16 M Private placement after listing $10 to $50 million 26
Kala Pharmaceuticals, Inc.: Private sale, Nov 2021 × Investors in this round 26 investors had bought by the notice of Nov 29, 2021: 26 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $16 M of $37 M offered; $20 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Darius Daniel Kharabi · Executive Officer Eric L. Trachtenberg · Executive Officer Hongming Chen · Executive Officer Kim Brazzell · Executive Officer Mark Iwicki · Executive Officer, Director Mary Reumuth · Executive Officer Todd Bazemore · Executive Officer Andrew L. Koven · Director C. Daniel Myers · Director Gregory D. Grunberg · Director Gregory D. Perry · Director Howard B. Rosen · Director Mark S. Blumenkranz · Director Robert D. Paull · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The total offering amount includes up to $20.4 million of shares of common stock that may be issued by the Issuer upon the achievement of specified milestones. The total amount sold includes $2,015,224 of shares subject to a post-closing holdback.”Signed by Mary Reumuth, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 29, 2021. Read the notice at the SEC .
equity SEC Apr 2016 $68 M No. 7 $50 to $250 million 25
Kala Pharmaceuticals, Inc.: Raise no. 7, Apr 2016 × Investors in this round 25 investors had bought by the notice of Apr 13, 2016: 25 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $68 M of $68 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Charles B. McDermott · Executive Officer Hongming B. Chen · Executive Officer Kim Brazzell · Executive Officer Mark Iwicki · Executive Officer, Director Chen B. Yu · Director Greg Grunberg · Director Howard B. Rosen · Director Kevin Bitterman · Director Rajeev B. Shah · Director Robert Langer · Director Robert Paull · Director Robert Tepper · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Mark Iwicki, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 13, 2016. Read the notice at the SEC .
equity SEC Aug 2015 $7 M No. 6 $2 to $10 million 1
Kala Pharmaceuticals, Inc.: Raise no. 6, Aug 2015 × Investors in this round 1 investor had bought by the notice of Aug 19, 2015: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $7 M of $7 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Charles B. McDermott · Executive Officer Hongming B. Chen · Executive Officer Kim Brazzell · Executive Officer Mark Iwicki · Executive Officer, Director Howard B. Rosen · Director Karen Wagner · Director Kevin Bitterman · Director Rajeev B. Shah · Director Robert Langer · Director Robert Paull · Director Robert Tepper · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Charles McDermott, President. Source: SEC Form D, newest notice filed Aug 19, 2015. Read the notice at the SEC .
equity SEC Apr 2014 $23 M No. 5 $10 to $50 million 16
Kala Pharmaceuticals, Inc.: Raise no. 5, Apr 2014 × Investors in this round 16 investors had bought by the notice of Apr 24, 2014: 16 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $23 M of $23 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Guillaume Pfefer · Executive Officer, Director Kim Brazzell · Executive Officer Bernard Gilly · Director Howard B. Rosen · Director Kevin Bitterman · Director Robert Langer · Director Robert Paull · Director Robert Tepper · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Guillaume Pfefer, President and CEO. Source: SEC Form D, newest notice filed Apr 24, 2014. Read the notice at the SEC .
equity SEC Feb 2013 $6 M No. 4 $2 to $10 million 10
Kala Pharmaceuticals, Inc.: Raise no. 4, Feb 2013 × Investors in this round 10 investors had bought by the notice of Feb 28, 2013: 10 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $6 M of $12 M offered; $6 M still to sell
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Andrea Franz · Executive Officer Guillaume Pfefer · Executive Officer, Director Bernard Gilly · Director Kevin Bitterman · Director Robert Langer · Director Robert Paull · Director Robert Tepper · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Andrea Franz, Treasurer and Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 28, 2013. Read the notice at the SEC .
equity SEC Feb 2012 $7 M No. 3 $2 to $10 million 10
Kala Pharmaceuticals, Inc.: Raise no. 3, Feb 2012 × Investors in this round 10 investors had bought by the notice of Mar 14, 2012: 10 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $7 M of $7 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Hongming Chen · Executive Officer Kevin Pojasek · Executive Officer Peter Courossi · Executive Officer Robert Paull · Executive Officer, Director Justin Hanes · Director Kevin Bitterman · Director Robert Langer · Director Robert Tepper · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Kevin Pojasek, Secretary and Vice President, Corporate Development. Source: SEC Form D, newest notice filed Mar 14, 2012. Read the notice at the SEC .
equity SEC Oct 2010 $3 M No. 2 $2 to $10 million 9
Kala Pharmaceuticals, Inc.: Raise no. 2, Oct 2010 × Investors in this round 9 investors had bought by the notice of Nov 10, 2010: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity, debt
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Robert Paull · Executive Officer, Director Justin Hanes · Director Kevin Bitterman · Director Robert Langer · Director Robert Tepper · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Robert Paull, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 10, 2010. Read the notice at the SEC .
equity, debt SEC Dec 2009 $2 M No. 1 $2 to $10 million 10
Kala Pharmaceuticals, Inc.: Raise no. 1, Dec 2009 × Investors in this round 10 investors had bought by the notice of Dec 23, 2009: 10 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Robert Paull · Executive Officer, Director, Promoter Justin Hanes · Director Robert Langer · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Robert Paull, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 23, 2009. Read the notice at the SEC .
equity SEC